Nephrotic Syndrome and Low Effective Circulating Volume (ECV)

Pathophysiological Mechanism

Nephrotic syndrome causes low effective circulating volume primarily through hypoalbuminemia, which leads to decreased oncotic pressure, fluid shifting from intravascular to interstitial spaces, and subsequent intravascular volume depletion, as noted by the National Kidney Foundation 1, 2
Massive proteinuria in nephrotic syndrome causes urinary loss of albumin and other proteins, resulting in hypoalbuminemia, according to the Kidney International guidelines 2, 3
Decreased serum albumin reduces plasma oncotic pressure, causing fluid to shift from the intravascular space to the interstitial space, as reported by the Nature Reviews Nephrology 1, 4

Symptoms suggestive of hypovolemia include prolonged capillary refill time, tachycardia, hypotension, oliguria, and abdominal discomfort, as indicated by the American Heart Association 1, 4
Despite overall fluid overload (edema), patients may paradoxically have intravascular volume depletion, as noted by the European Renal Association 5

Increased risk of thromboembolism (29% for renal vein thrombosis, 17-28% for pulmonary embolism, 11% for deep vein thrombosis) is associated with nephrotic syndrome, as reported by the Kidney International guidelines 2, 3
Increased morbidity and mortality (a decrease of 1.0 g/dL in serum albumin increases odds of morbidity by 89% and mortality by 137%) is linked to low effective circulating volume, according to the National Kidney Foundation 2, 3

Albumin infusions (1-4 g/kg) should be administered to support intravascular volume in patients with symptomatic hypovolemia, as recommended by the Nature Reviews Nephrology 1, 4
The purpose of albumin infusion is not to normalize serum albumin levels but to support intravascular volume and reduce extravascular fluid retention, as noted by the American College of Physicians 1, 5
Diuretics should be used with caution and only in cases of intravascular fluid overload, as they could worsen hypovolemia and promote thrombosis, according to the European Renal Association 1, 4

Regular assessment of volume status through clinical indicators of hypovolemia is essential, as indicated by the National Kidney Foundation 1, 5
Monitor serum albumin levels, but base treatment decisions on clinical indicators rather than albumin levels alone, as recommended by the American Heart Association 1, 4
Evaluate for signs of thromboembolism, which is a significant risk in patients with nephrotic syndrome and hypovolemia, as reported by the Kidney International guidelines 2, 3